Frontiers in Immunology (Mar 2024)
Corrigendum: Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes
- Nyerhovwo Obarorakpor,
- Deep Patel,
- Reni Boyarov,
- Nansalmaa Amarsaikhan,
- Joseph Ray Cepeda,
- Doreen Eastes,
- Sylvia Robertson,
- Travis Johnson,
- Travis Johnson,
- Travis Johnson,
- Travis Johnson,
- Kai Yang,
- Kai Yang,
- Qizhi Tang,
- Qizhi Tang,
- Qizhi Tang,
- Li Zhang,
- Li Zhang,
- Li Zhang
Affiliations
- Nyerhovwo Obarorakpor
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Deep Patel
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Reni Boyarov
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Nansalmaa Amarsaikhan
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Joseph Ray Cepeda
- Department of Medicine, Endocrinology, Diabetes & Metabolism, Baylor College of Medicine, Houston, TX, United States
- Doreen Eastes
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Sylvia Robertson
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Travis Johnson
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Travis Johnson
- Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, United States
- Travis Johnson
- Melvin and Bren Simon Comprehensive Cancer Center, Experimental and Developmental Therapeutics, School of Medicine, Indiana University, Indianapolis, IN, United States
- Travis Johnson
- Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, United States
- Kai Yang
- Herman B Wells Center for Pediatric Research and Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
- Kai Yang
- School of Medicine, Indiana University Bloomington, Bloomington, IN, United States
- Qizhi Tang
- Diabetes Center, University of California San Francisco, San Francisco, CA, United States
- Qizhi Tang
- Department of Surgery, University of California San Francisco, San Francisco, CA, United States
- Qizhi Tang
- 0Gladstone Institute of Genomic Immunology, University of California San Francisco, San Francisco, CA, United States
- Li Zhang
- Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- Li Zhang
- 1Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, United States
- Li Zhang
- 2Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, United States
- DOI
- https://doi.org/10.3389/fimmu.2024.1391518
- Journal volume & issue
-
Vol. 15
Abstract
No abstracts available.Keywords
- Type 1 diabetes
- regulatory T cell
- chimeric antigen receptor
- antigen specific immunotherapy
- MHC II/Insulin complex
- monoclonal antibody